Alzheimer's tau vaccine study (AADvac1)
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a vaccine that targets tau tangles in the brain, which are linked to Alzheimer's. It is part of a larger platform study that combines different experimental treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must qualify for the main Alzheimer's Tau Platform study (check its requirements).
- You have a diagnosis of early Alzheimer's disease or mild cognitive impairment due to Alzheimer's.
- You have evidence of tau buildup on a brain scan (like PET).
- You are willing to receive multiple injections of the study vaccine.
- You do not have any medical conditions or medications that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This study tests a vaccine that targets tau protein, which is linked to Alzheimer's disease. It is for older adults who have no memory problems yet but have biological signs of early Alzheimer's, to see if the vaccine can prevent or slow down the disease.
This trial tests an experimental vaccine (DUVAX) that targets two proteins linked to Alzheimer's disease: amyloid-beta and tau. It is an early-stage study to check safety and see how the body responds, aiming to prevent or delay the disease.
This trial tests a vaccine that may help the immune system clear a protein linked to Alzheimer's disease. It is for people who do not have memory problems yet but have signs of the disease in their blood or brain scans.
This trial tests a monthly infusion drug called donanemab, which aims to clear amyloid plaques (a hallmark of Alzheimer's) from the brain, potentially slowing memory decline in people with early Alzheimer's disease. Participants will receive the drug as part of this study.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
Hear when a new Preclinical Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.